Breaking News

Chiltern, Karolinska Development Enter Strategic Partnership

By Kristin Brooks | February 12, 2014

Seeks to develop innovative products to sell or out-license

Chiltern International Ltd. has entered into a partnership with Karolinska Development in Sweden, a life science investment company, to develop innovations, using world-class science, into products that can be sold or out-licensed with the goal of high returns.
 
"We are extremely pleased to be selected as the partner CRO for Karolinska Development after an extensive CRO selection process in 2012. We were selected based on our compatibility with Karolinska Development's specific development needs in terms of our global company infrastructure and our approach to deliver innovation, quality and flexibility to every project," said Dr. Jim Esinhart, chief executive officer of Chiltern.
 
Aize Smink, Chiltern's chief operating officer, said, "We are honored and proud to be partnering with Karolinska Development, a world-class organization committed to life science innovations and bringing novel therapies to market. A key aspect of our partnering is our early involvement in the development of studies and providing support services and consultation as needed in the product lifecycle. Together, we will work closely with the core team at Karolinska Development to achieve the goals and objectives of their pipeline.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent